About Aeovian Pharmaceuticals
Aeovian Pharmaceuticals is a private company based in Berkeley, California. It has reported $125,000,667 raised in four offerings on Form D since June 2017. Its chief executive is Allison Hulme.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Nov 18, 2025 | Dec 22, 2025 | $54,999,996fully sold | 13 | $4.2M | EquityRule 506(b) | Form D ↗ |
| Dec 22, 2023 | May 13, 2024 | $50,415,077fully sold | 5 | $10.0M | EquityRule 506(b) | Form D ↗ |
| Sep 24, 2019 | Oct 9, 2019 | $18,799,907of $48.7M target | 5 | $3.7M | EquityRule 506(b) | Form D ↗ |
| Jun 14, 2017 | Jun 28, 2017 | $785,687of $3.7M target | 4 | $196K | EquityRule 506(b) | Form D ↗ |
| Total, four offerings | $125,000,667 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Aeovian Pharmaceuticals's Form D filed Dec 22, 2025.
Earlier filings also listed Matthew Plunkett (executive officer, last listed May 2024), Lars Ekm (director, last listed May 2024), Stelios Tzannis (chief executive officer and director, last listed Oct 2019), Michael Powell (director, last listed Oct 2019), Jens Eckstein (director, last listed Oct 2019), Ben Zadik (executive officer, last listed Oct 2019), James Peyer (director, last listed Jun 2017) and Ian Massey (executive officer, last listed Jun 2017).